NCT03186313View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

November 30, 2017

Conditions
Hepatitis C
Interventions
DRUG

Dactavira Plus

1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.

DRUG

Sofosbuvir + Daclatasvir + Ribavirin

Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.

DRUG

Dactavira

Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks

DRUG

Sofosbuvir + Daclatasvir

Daily dose Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks

Trial Locations (1)

35681

Egyptian Liver Hospital, Sherbin

All Listed Sponsors
collaborator

Wadi El Nil Hospital

UNKNOWN

lead

Egyptian Liver Hospital

OTHER

NCT03186313 - A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection | Biotech Hunter | Biotech Hunter